The ME Association, a national charity based in Gawcott, Bucks, has announced its investment in a major clinical trial in Canada to study the effects of low-dose naltrexone (LDN) on ME, chronic fatigue syndrome (CFS) and Long Covid.
The trial, led by Dr. Luis Nacul at the University of British Columbia, will investigate whether LDN can alleviate symptoms like fatigue, pain, and sleep disturbances while reducing inflammation.
With no current cure for ME/CFS or Long Covid, the study aims to provide crucial evidence on LDN’s potential benefits. If successful, it could pave the way for wider use of the drug in the UK. Dr. Charles Shepherd, the ME Association’s medical advisor, emphasized the urgent need for effective treatments, highlighting the significant impact these conditions have on individuals and healthcare systems.
The double-blind, placebo-controlled trial is set to conclude by December 2025, with results expected in early 2026.
The ME Association in Bucks hopes this research will contribute to better treatment options for those suffering from these debilitating conditions.
More than 3,000 in Bucks took part in scientific research last year
Runners in Bucks come together to support Chilterns Neuro Centre
Ponies bring joy to Florence Nightingale Hospice in Aylesbury
Waddesdon Manor to shut over Christmas this year
Wycombe MP takes senior role in Prime Minister's new government
Aylesbury in Bloom Schools' Competition winners revealed
Aylesbury School achieves national accreditation for excellence in education technology
RSPCA caring for 20 rabbits after a number were dumped in a country park
